4 Laboratory Diagnostic Testing for Borrelia burgdorferi Infection

Barbara J.B. Johnson

4.1 Introduction

Serology is the only standardized type of laboratory testing available to support the clinical diagnosis of Lyme borreliosis (Lyme disease) in the USA. It is also the only type of diagnostic testing approved by the US Food and Drug Administration (FDA). Of the 77 devices cleared by the FDA for in vitro diagnostic use for Lyme disease, all are designed to detect immune responses to antigens of Borrelia burgdorferi sensu stricto, particularly IgM and IgG (FDA, 2010). Serological tests do not become positive until an infected individual has had time to develop antibodies. In Lyme disease, this means that early acute disease characterized by an expanding rash (erythema migrans or EM) at the site of a tick bite cannot be reliably diagnosed by serology. After a few weeks of infection, however, immunocompetent people will have made enough antibodies that serology is useful for confirming exposure to B. burgdorferi in all subsequent stages of Lyme disease. Antibody levels remain elevated for months to years after the infection is cured.

A variety of direct tests for the agent of Lyme borreliosis have been developed. Direct tests include culture of Borrelia from skin or blood and occasionally cerebrospinal fluid (CSF), and detection of genetic material by PCR in skin, blood, synovial fluid and CSF. These tests have specialized roles in research and in academic and reference laboratories but are not available for routine use. Culture and PCR each have distinct limitations that will be noted in this chapter.

Diagnostic tests are of clinical value only if they are used appropriately. This has become particularly important in the field of diagnostic testing for Lyme disease, as both patients and doctors hear conflicting information about the risk of Lyme disease in various environments. Furthermore, patients are sometimes given laboratory diagnostic tests when they lack objective signs of Lyme disease and a history of potential exposure to infected vector ticks. A healthcare provider must estimate the pre-test likelihood that a patient has Lyme disease in order to understand the positive and negative predictive values of tests for Lyme disease. Fortunately, there are resources available to assist providers in making this judgement.

It is important to know that laboratories may offer ‘in-house’ testing for Lyme disease.
that does not require review and approval by the FDA. Because some in-house tests have not been rigorously developed and validated, the Centers for Disease Control and Prevention (CDC) and FDA recommend that these tests only be used when their accuracy and clinical usefulness have been documented in peer-reviewed scientific literature (CDC, 2005). Unvalidated tests as of 2010 include capture assays for antigens in urine, immunofluorescence staining or cell sorting of cell wall-deficient or cystic forms of B. burgdorferi, lymphocyte transformation tests, quantitative CD57 lymphocyte assays, 'reverse Western blots' (Feder et al., 2007), in-house criteria for interpretation of immunoblots and measurements of antibodies in synovial fluid.

This chapter considers the diagnostic testing for B. burgdorferi sensu stricto infection, the only organism established to cause Lyme disease in North America. Lyme disease also results from infection by Borrelia garinii or Borrelia afzelii in Europe and Asia, as well as by the recently described Borrelia spielmanii in Europe (Wang et al., 1999; Richter et al., 2006; Fingerle et al., 2008). Borrelia valaisiana and Borrelia turicatae have been associated anecdotally with Lyme disease in some parts of Europe (Crowder et al., 2010), particularly B. lusitaniae in Portugal (Collares-Pereira et al., 2004). Borrelia bissettii has been cultured from a few patients in Europe (Strle et al., 1997), but has not been shown to cause human disease in North America. Diagnostic tests for B. burgdorferi sensu stricto will not necessarily perform well for infections by other genospecies of Lyme disease bacteria, although some do (e.g. assays based on the C6 peptide of the variable surface antigen (VlsE) or the whole VlsE protein). Guidelines for laboratory diagnosis of European Lyme borreliosis are available online in English (Health Protection Agency of the UK, 2010; German Society for Hygiene and Microbiology, 2000).

4.2 Two-tiered Serology: the Current Standard for Serodiagnosis in North America

The public health agencies of the USA and Canada advocate a two-step process for measuring antibodies in blood when Lyme disease is suspected. The CDC recommends two-tiered testing both for the evaluation of individual patients (CDC, 1995) and for epidemiological surveillance for Lyme disease (CDC, 1997). This recommendation was developed with the participation of the relevant major agencies of the USA, including the FDA, the National Institutes of Health, the Council of State and Territorial Epidemiologists, the Association of Public Health Laboratories and the Clinical Laboratory Standards Institute (ASTPHLD and CDC, 1995). The Canadian Public Health Laboratory Network (2007) guidelines also recommend two-tiered testing. The Infectious Diseases Society of America (IDSA) has endorsed two-tiered serology to support the diagnosis of Lyme disease in patients who have manifestations other than acute EM (Wormser et al., 2006).

A schematic summarizing the features of two-tiered serology is shown in Fig. 4.1. The first tier consists of a sensitive initial serological test or tests that detect class-specific antibodies (IgM and IgG, either together or separately). First-tier tests are enzyme immunoassays (EIAs) such as ELISAs or, rarely today, indirect immunofluorescence assays (IFAs) as they require a skilled microscopist and cannot be scored objectively. If the result of first-tier testing is negative, the serum is reported to be negative for antibodies to B. burgdorferi and is not tested further. If the result is positive or indeterminate (a value that is sometimes called 'equivocal' or 'borderline'), a second step should be performed. The indeterminate category is the range of test values that overlaps between Lyme disease patients and...

---

2 The latter two were known at the time as the Association of State and Territorial Public Health Laboratory Directors (ASTPHLD) and the National Committee for Clinical Laboratory Standards (NCCLS), respectively.
controls and is specific to each test. Further information is needed from a second test in order to call the specimen positive or negative.

The second tier consists of standardized immunoblotting, either by using Western blots or blots striped with diagnostically important purified antigens. When an IgG immunoblot is scored as positive (Dressler et al., 1993; CDC, 1995), two-tiered testing is reported as positive. When an IgM immunoblot is scored as positive (Engstrom et al., 1995; CDC, 1995), Lyme disease serology is reported as positive with the caveat that this finding is clinically relevant only in early disease, that is, in the first month of illness (ASTPHLD and CDC, 1995; CDC, 1995). Immunoblots and the recommended criteria for scoring them are shown in Fig. 4.2. These scoring criteria have been validated for antibodies to *B. burgdorferi* sensu stricto, the agent of Lyme disease in North America, but not for immune responses to other genospecies of *Borrelia*.

Two-tiered serology is considered positive only if the EIA (or IFA) and the immunoblot are both positive. Skipping either step increases the frequency of false-positive results (see below).

First-tier tests commonly use whole-cell antigens of *B. burgdorferi* grown in vitro. The immunodominant antigen VlsE also has been

---

**Two-tiered serology**

*(immunoblotting conditionally supplements EIAs)*

**Tier 1: IgG or IgM EIAs (combined or separate)**

- Positive or indeterminate
  - **Negative**
    - Reported as negative; two-tiered protocol complete

**Tier 2: IgG and/or IgM immunoblots (separate)**

- Either blot positive
  - IgG-positive reported as positive
  - IgM-positive reported as positive
    - BUT clinically relevant only in early disease of less than 1 month duration
  - Reported as negative

Fig. 4.1. Two-tiered serology for Lyme disease.
approved by the FDA. One small portion of VlsE, a 26 amino acid peptide called C6 that reproduces the sixth constant region of the protein, was authorized by the FDA for commercial use (Immunetics) as a first-tier test in 2001 (Liang et al., 1999; FDA, 2010). A diagnostic assay containing entire VlsE molecules expressed as recombinant proteins from both B. burgdorferi and B. garinii (Diasorin) became available as a first-tier test in 2007 (Lesbias et al., 2006; FDA, 2010). C6- and VlsE-based assays have the additional feature of detecting antibodies to Eurasian genospecies of Borrelia (i.e. B. garinii and B. afzelii) as well as B. burgdorferi sensu stricto.

An extensive peer-reviewed scientific literature supports the rationale for and performance of two-tiered serological testing. This algorithm has been validated in both retrospective and prospective studies. The specificity of two-tiered testing is high – 99% or greater in diagnostic reference centres. The sensitivity is also high after the acute phase of EM. Patients with Lyme arthritis or late neuroborreliosis are nearly always seropositive (97–100%). The rate of seropositivity is lower in patients with acute-phase early neurological disease (80–100%, depending on the population studied). This stage of Lyme disease in particular is the subject of research to improve the sensitivity of serodiagnosis (Dressler et al., 1993; Engstrom et al., 1995; Johnson et al., 1996; Bacon et al., 2003; Peltomaa et al., 2004; Aguero-Rosenfeld et al., 2005; Steere et al., 2008; Branda et al., 2010; Wormser et al., 2011; and others).

Patients often inform themselves about diagnostic testing for Lyme disease before visiting a physician. Unfortunately, the quality of information available on the Internet varies widely and some is not evidence-based (Cooper and Feder, 2004). Here are some questions that are commonly asked:

1. Aren’t ELISA tests insensitive and therefore unsuitable as first-tier tests?
2. Aren’t immunoblots more sensitive than ELISA tests? Shouldn’t they be used instead of two-tier testing?
3. Why do the recommended blot scoring criteria ignore outer-surface protein A (OspA) and OspB? OspA was used as a vaccine, so why isn’t it scored in serology?
4. Why are you disregarding my IgM test result just because I have had this illness for years?
8. How sensitive is serology in late Lyme disease? How can you be sure, as seropositivity is part of the case definition for Lyme disease, except in patients with EM? Each of these questions will be addressed with reference to the scientific literature.

4.2.1 How sensitive are ELISAs?

The sensitivity of first-tier tests varies by stage of Lyme disease. The antibody response to *B. burgdorferi* develops over the first few weeks after the spirochaete is introduced into the body, in a fashion similar to other bacterial infections. Patients with EM are often seronegative at the time of presentation, as EM can precede the development of a measurable antibody response. The probability of seroreactivity increases with duration of EM and with the development of signs of disseminated disease (Aguero-Rosenfeld et al., 1993, 1996; Johnson, 2006).

Although 60% or less of EM patients test positive by ELISA during acute disease, by convalescence 80–90% of treated EM patients are seropositive (Aguero-Rosenfeld et al., 1993, 1996; Engstrom et al., 1995; Bacon et al., 2003; Johnson et al., 2004; Johnson, 2006). The well-known insensitivity of ELISAs in acute EM is the reason that the CDC and IDSA do not advocate serological testing of these patients. It is appropriate to treat patients who have rashes compatible with EM with antibiotics based on clinical presentation alone.

The controversies about serological testing do not generally concern test performance in patients with EM, of course. Fortunately, after the first weeks of illness, the sensitivity of first-tier serology is excellent. Numerous published studies indicate that the sensitivity of whole-cell-lysate ELISAs is essentially 100% after the EM stage of illness (e.g., Dressler et al., 1993; Bacon et al., 2003; Johnson et al., 2004; Johnson, 2006). Antibody levels remain elevated for months to years following antibiotic therapy (Engstrom et al., 1995; Aguero-Rosenfeld et al., 1996; Kalish et al., 2001). Because IgM antibody levels may remain elevated after treatment, a single positive IgM ELISA test does not necessarily support the diagnosis of a new *B. burgdorferi* infection.

How did the misconception arise that ELISAs are insensitive in stages of Lyme disease other than EM? Firstly, studies are often cited that describe tests that are obsolete and no longer used. For example, a study conducted in 1992–1994, before two-tiered testing was recommended as a national standard, is commonly quoted (Bakken et al., 1997). Many early ELISAs were designed to be stand-alone tests. Some tests were insensitive in order to achieve better specificity using whole-cell lysates. Despite this, false-positive results with some serum samples from healthy donors approached 55% (Bakken et al., 1997). Of the 29 ELISAs approved by the FDA before 1993 (FDA, 2010), only three were used recently by a few laboratories (20/417) that participated in a College of American Pathologists (CAP) proficiency testing programme (CAP, 2009). Most ELISAs in current commercial use are sufficiently sensitive to perform well in a two-tiered testing scheme after the EM stage of illness (Aguero-Rosenfeld et al., 1993; Bacon et al., 2003; Johnson et al., 2004; Johnson, 2006). The excellent performance of ELISAs in proficiency tests can be reviewed by subscribers to the surveys carried out by CAP (2009), although it must be kept in mind that only a small number of samples were used in each evaluation.

Secondly, the misconception that ELISAs are insensitive in later Lyme disease is supported by inappropriately applying data from patients with EM, for whom serological testing is not recommended, and then claim that ELISAs are poor in diagnosing infections of longer duration.
4.2.2 Why not skip the ELISA and go directly to immunoblots?

It is important to appreciate that first- and second-tier tests are not independent indicators of exposure to *B. burgdorferi* (Wormser et al., 2000). ELISAs and immunoblots are usually constructed with the same antigens – whole-cell antigens of bacteria grown in culture – but they are processed differently. There is no prior reason for immunoblots to be more sensitive than ELISAs. ELISAs provide an estimate of the magnitude of the IgG/IgM humoral antibody response to all of the antigens that are expressed under the culture conditions used to produce the whole-cell antigen or to the recombinant or peptide antigens used. ELISA results are objective and quantitative. They can be correlated with antibody titres. Immunoblotting techniques, in contrast, separate the many bacterial antigens spatially on a solid support so that the specificity and complexity of the antibody responses are revised. Immunoblots are qualitative or, at best, semi-quantitative tests (Fig. 4.2).

The rationale for determining IgM and IgG antibody profiles by immunoblotting is to learn whether a patient’s antibodies recognize proteins of *B. burgdorferi* that have been established to be more predictive of Lyme disease than other components of the bacteria (Dreesk et al., 1993; Engstrom et al., 1995). Many antigens have similarities to those of other organisms, such as proteins involved in motility (e.g. flagellin) and responses to stress (e.g. ‘heat-shock’ proteins). Recognition of one or more antigens from this set by serum antibodies is not necessarily indicative of exposure to *B. burgdorferi*, although these reactions contribute to the signal strength measured in an ELISA. ELISAs for Lyme disease commonly may give false-positive results (up to ~5%) in patients with other spirochaetal diseases such as tick-borne relapsing fever, syphilis or *Leptospira* infections and bacterial endocarditis, although this has not been well studied (Kaell et al., 1993). In addition, non-infectious conditions within the differential diagnosis of Lyme disease yield false-positive rates of around 10%, depending on the patients studied. Cross-reactions are sometimes seen in serum from patients with anti-nuclear antibodies, rheumatoid factor, clinical rheumatoid arthritis or multiple sclerosis (Johnson et al., 2004; Johnson, 2006).

Omitting an ELISA as a first-tier test and using immunoblot results alone decreases the specificity of serological testing. Decreased specificity has been observed both with serum samples from healthy blood donors from non-endemic areas and with samples from patients with other illnesses within the differential diagnosis of Lyme disease. For donors, the decrease in specificity was from 100% for two-tiered testing to 92% for blotting alone in a study by Engstrom et al. (1995) and from 100 to 96.5% in work by Johnson et al. (1996). In patients with other illnesses, there was a 4% decrease from 100% specificity for two-tiered testing to 96% for blotting alone (Johnson et al., 1996).

Seemingly small changes in specificity have large public health impacts. The volume of laboratory diagnostic testing for Lyme disease has recently been evaluated. In 2008, more than 3.4 million tests for Lyme disease were performed in the USA (A. Hinckley, CDC, 2010; personal communication). Each 1% decrease in testing specificity would generate about 34,000 false-positive results per year. To put this number in context, 38,468 cases of Lyme disease (confirmed plus probable) were reported to the CDC as part of the US national system for surveillance of notifiable diseases in 2009 (Bacon et al., 2008; CDC, 2011).

Why does specificity decrease if immunoblotting alone is used? The Clinical Laboratory Standards Institute identifies one
Laboratory Diagnostic Testing for *Borrelia burgdorferi* Infection

reason: 'The erroneous scoring of a faint band is a common reason for false-positive readings…' (NCCLS, 2000). IgM results are more affected by this problem than IgG blots. In general, IgM antibodies are more nonspecifically ‘sticky’ than IgG antibodies, in part because of their pentameric structure in serum compared with monomeric IgG. In addition, only two of three specified bands are required for an IgM blot to be reported as positive, whereas five of ten bands are necessary for an IgG blot to be positive by the recommended blot interpretation criteria (CDC, 1995; Fig. 4.2). Consequently, a single erroneously scored faint band will affect IgM results more readily than it will affect IgG results.

Faint bands, particularly in IgM blots, may not be diagnostically significant even for so-called ‘specific’ antigens. If healthcare providers adhere to the recommendation to demonstrate that antibodies are present at a positive or indeterminate level by a first-tier test before ordering an immunoblot, the risk of an erroneously positive serology based on scoring faint bands is reduced but not eliminated.

4.2.3 Why don’t the scoring criteria for immunoblots include OspA and OspB?

The bands at the 31 and 34 kDa positions of immunoblots are produced by OspA and OspB, respectively (Fig. 4.2). It has been recognized since the early 1990s that antibodies to OspA and OspB are infrequently detected and when they are observed, it is usually in patients with longstanding Lyme arthritis. Ma et al. (1992) wrote that ‘:…antibodies against the 31- and 34kDa proteins were rarely detected and, consequently, became less significant when compared with other protein bands in this study’. Steere’s laboratory reported in Dressler et al. (1992) that, although antibodies to OspA and OspB were detectable in some patients with Lyme arthritis or late neurological disease, the frequency of antibody responses to these polypeptides was not as high as to ten other antigens. Blot interpretation criteria that could best discriminate Lyme disease patients from controls therefore did not include scoring antibodies to OspA or OspB. When hands at 31 or 34 kDa are observed, they are virtually always in the context of a robust IgG response to a large number of scored antigens.

Patients may inquire specifically about why OspA is not scored when it was the basis for an effective vaccine (ILADS, 2010). People naturally think of the usual way that vaccines work, neutralizing infection in a mammalian host, and expect a vaccine antigen to be a good diagnostic antigen. They may be unaware that the OspA vaccine works by killing *B. burgdorferi* in vector ticks as they feed (de Silva et al., 1996). OspA is well expressed by *B. burgdorferi* in unfed ticks and is a suitable target for antibodies that enter a tick during a blood meal from an OspA-vaccinated host. When ticks are exposed to a blood meal and the body temperature of a mammal, *B. burgdorferi* stops expressing OspA (Schwan and Piesman, 2000). Another outer-surface protein, OspC, is expressed instead. Reciprocal expression of these two OspS has been demonstrated at the level of single cells (Srivastava and de Silva, 2008). It is not surprising, therefore, that antibody responses to OspC are diagnostically useful in early Lyme disease, but responses to OspA are lacking.

In later manifestations of Lyme disease, especially Lyme arthritis, some people develop antibodies to OspA and/or OspB. OspA expression is upregulated in an inflammatory milieu such as an arthritic joint. OspA expression can be artificially upregulated in a controlled in vivo environment by exposure to zymosan, a yeast cell-wall extract that induces inflammation (Kalish et al., 1993; Crowley and Huber, 2003). Thus, it is no longer a paradox that *B. burgdorferi* expresses little or no OspA as it is transmitted to mammalian hosts, but that OspA can be produced late in the course of untreated Lyme disease.

Some claim that patients should be judged seropositive based on finding immunoblot bands solely at the 31 or 34 kDa positions, even when their serum is negative by an ELISA that uses whole-cell antigens. However, *B. burgdorferi* grown in culture expresses OspA and OspB abundantly (Crowley and Huber, 2003) and ELISAs made
from cultured whole cells contain these antigens. Thus, samples from patients who have diagnostically significant levels of antibodies to OspA or OspB will react in a whole-cell-lysate ELISA. When an ELISA is negative but an immunoblot of the same sample is scored positive, it is probable that faint immunoblot bands are being ‘over-read’.

4.2.4 When is IgM testing clinically useful?

IgM testing should be performed only in patients with early Lyme disease, defined by the CDC (1995) as within the first month of infection. Some investigators have suggested recently that IgM responses may have diagnostic utility for an additional 2 weeks (Branda et al., 2010), and personal communication. Whether the cutoff for IgM testing is best set at 4 or 6 weeks, IgM testing is appropriate only during a limited early time window. Recall also that serological testing is not useful in patients with EM, the earliest manifestation of Lyme disease, simply because antibodies have not yet had time to develop. This further restricts the clinical utility of IgM testing.

Some physicians use IgM serology to assess patients with longstanding illness (many months to years). They point to the new IgM responses to OspB that have been observed to develop late in infection in patients with prolonged disease. This new IgM response, however, occurs in the context of a robust IgG response to a large number of the antigens in the recommended IgG scoring criteria (Kalish et al., 1993). The existence of a new IgM response in Lyme arthritis patients is not good evidence that IgM serology alone, and especially not IgM immunoblotting alone, can properly support the diagnosis of late Lyme disease.

During the month or so after initial infection, antibodies rise in titre, recognize an increasing number of borrelial antigens and switch class from a predominantly IgM response to IgG. The evolution of the immune responses during early infection is illustrated by the serological findings in patients with early neurological disease. In a study of patients with facial paralysis, 87% had diagnostic levels of IgM antibodies, 66% were IgG positive and all were seropositive for at least one antibody class (Niittymaa et al., 2004).

This profile of antibody reactivity by class (i.e. a greater frequency of positive IgM responses than IgG, with many people seropositive for both classes) also is seen in patients with other manifestations of early neurological disease, typically meningitis and/or radiculoneuritis (Roux et al., 2007). In the event that a patient with a suspected early manifestation of Lyme disease is seronegative, CDC guidelines note that ‘serologic evidence of infection is best obtained by testing of paired acute- and convalescent-phase samples’ (ASTPHLD and CDC, 1995) obtained several weeks apart.

By the time patients develop later manifestations of Lyme disease, they are almost universally seropositive for IgG (Droosler et al., 1993; Kannian et al., 2007). Numerous studies with robust sample sizes have been published about the immune responses in Lyme arthritis. Patients with Lyme arthritis typically have high IgG titres, higher than those seen in any of the other various manifestations of Lyme disease, and waning IgM responses.

Late neurological Lyme disease, presenting as encephalomyelitis, peripheral neuropathy or encephalopathy, is rare (Wormser et al., 2006; Halperin et al., 2007). It has been speculated that late neuroborreliosis has become rarer in recent years due to earlier diagnosis and treatment, preventing progression to late-stage manifestations. Serum IgG antibodies have been found consistently in patients who have been available for study (Droosler et al., 1993; Bacon et al., 2003).

For these reasons, the CDC does not recommend the use of IgM responses in the absence of diagnostic levels of IgG antibodies to support the diagnosis of any manifestation of Lyme disease after 1 month of illness. Furthermore, as noted by Sivak et al. (1996), the predictive value of a positive IgM blot is ‘poor in patients with minimal clinical evidence of Lyme disease’.

4.2.5 Why is serodiagnosis of late Lyme disease difficult?

IgM responses are particularly problematic in late Lyme disease. The CDC’s recommendation to use serodiagnosis in late Lyme disease—‘a long time after the onset of illness’—largely is based on the observation that most people with late neurological Lyme disease have IgG responses to a large number of borrelial antigens, typically meningitis and/or radiculoneuritis (Roux et al., 2007). Thus, the difficulty here is not that late Lyme disease is difficult to diagnose, but that late Lyme disease is difficult to differentiate from other neurological infections.

Some investigators have suggested that IgM responses may have diagnostic utility for an additional 2 weeks (Branda et al., 2010), and personal communication. Whether the cutoff for IgM testing is best set at 4 or 6 weeks, IgM testing is appropriate only during a limited early time window. Recall also that serological testing is not useful in patients with EM, the earliest manifestation of Lyme disease, simply because antibodies have not yet had time to develop. This further restricts the clinical utility of IgM testing.

Some physicians use IgM serology to assess patients with longstanding illness (many months to years). They point to the new IgM responses to OspB that have been observed to develop late in infection in patients with prolonged disease. This new IgM response, however, occurs in the context of a robust IgG response to a large number of the antigens in the recommended IgG scoring criteria (Kalish et al., 1993). The existence of a new IgM response in Lyme arthritis patients is not good evidence that IgM serology alone, and especially not IgM immunoblotting alone, can properly support the diagnosis of late Lyme disease.

During the month or so after initial infection, antibodies rise in titre, recognize an increasing number of borrelial antigens and switch class from a predominantly IgM response to IgG. The evolution of the immune responses during early infection is illustrated by the serological findings in patients with early neurological disease. In a study of patients with facial paralysis, 87% had diagnostic levels of IgM antibodies, 66% were IgG positive and all were seropositive for at least one antibody class (Niittymaa et al., 2004).

This profile of antibody reactivity by class (i.e. a greater frequency of positive IgM responses than IgG, with many people seropositive for both classes) also is seen in patients with other manifestations of early neurological disease, typically meningitis and/or radiculoneuritis (Roux et al., 2007). In the event that a patient with a suspected early manifestation of Lyme disease is seronegative, CDC guidelines note that ‘serologic evidence of infection is best obtained by testing of paired acute- and convalescent-phase samples’ (ASTPHLD and CDC, 1995) obtained several weeks apart.

By the time patients develop late manifestations of Lyme disease, they are almost universally seropositive for IgG (Droosler et al., 1993; Kannian et al., 2007). Numerous studies with robust sample sizes have been published about the immune responses in Lyme arthritis. Patients with Lyme arthritis typically have high IgG titres, higher than those seen in any of the other various manifestations of Lyme disease, and waning IgM responses.

Late neurological Lyme disease, presenting as encephalomyelitis, peripheral neuropathy or encephalopathy, is rare (Wormser et al., 2006; Halperin et al., 2007). It has been speculated that late neuroborreliosis has become rarer in recent years due to earlier diagnosis and treatment, preventing progression to late-stage manifestations. Serum IgG antibodies have been found consistently in patients who have been available for study (Droosler et al., 1993; Bacon et al., 2003).

For these reasons, the CDC does not recommend the use of IgM responses in the absence of diagnostic levels of IgG antibodies to support the diagnosis of any manifestation of Lyme disease after 1 month of illness. Furthermore, as noted by Sivak et al. (1996), the predictive value of a positive IgM blot is ‘poor in patients with minimal clinical evidence of Lyme disease’.
4.2.5 How can you study the sensitivity of tests for Lyme disease when seropositivity is part of the definition of a case?

The clinical signs and symptoms of Lyme disease after the first weeks of infection are not unique to this illness. Clinical findings are not specific enough to permit a confident diagnosis without laboratory testing. As noted by Steere et al. (2008), “It is problematic to determine the frequency of seroreactivity in patients with neurological, cardiac, or joint manifestations of Lyme disease, because serological confirmation is a part of the case definition.” These considerations raise the important question of how to properly select serum samples for studying the performance of serological tests. To avoid circular reasoning, a previous positive serological result should not be the basis for inclusion of a specimen in such a study. However, independent assessment of infection status, for example by bacteriological culture, is routinely successful only in early disease (Aguren-Rosenfeld et al., 2005) and is generally performed only in research settings.

To approach this problem, investigators look to the natural history of untreated Lyme disease. Patients with late disease frequently have a documented history of earlier signs and symptoms of Lyme disease that support the clinical diagnosis. For selection of ‘gold standard’ specimens for assessment of serological test performance in later Lyme disease, serum from patients with antecedent clinical findings compatible with earlier Lyme disease are used. Supplementary research tests such as PCR add additional confidence to the classification of some specimens (Bradley et al., 1994; Nocton et al., 1994).

Patients with early neurological Lyme disease commonly have a history of recent EM. Lyme facial paralysis, for example, was associated with EM in 72–87% of patients, depending upon the study (Peltomaa et al., 2004). Patients with carditis, an uncommon presentation of Lyme disease that occurs in the early weeks of infection and manifests primarily as atrioventricular block, also typically have either previous or concurrent EM (>48%) or sometimes early neurological Lyme disease (Wormser et al., 2008). Patients with late neurological Lyme disease, a rare condition, generally have a history of other clinical manifestations of Lyme disease such as EM or Lyme arthritis. In a report by Bacon et al. (2003), 100% of 11 late neurological Lyme disease patients were seropositive. All of these patients had antecedent other clinical manifestations of Lyme disease that were the basis for including the serum samples in the study.

4.3 Newer Serological Tests

Two-tiered serology has good performance characteristics, that is, high sensitivity and specificity after the first weeks of B. burgdorferi infection. Experienced laboratories with good-quality control and quality assurance programmes obtain consistent results (e.g. Bacon et al., 2003; Kamian et al., 2007; CAP, 2009). Nevertheless, there are limitations to two-tiered testing that are being addressed by newer testing methods. As noted, two-tiered testing is insensitive in acute EM and may be negative in early neuroborreliosis. Other drawbacks are that the two-step procedure is complex, technically demanding and costly. Immunoblots are only semi-quantitative. Traditional blots are hard to standardize, as reading them involves judgement about the significance of weak bands. Other difficulties with two-tiered serology are the need to know the date of disease onset to appropriately request IgM testing and the inconvenience of sometimes having to draw a second blood sample. The latter may occur if the second test is indicated and the first test was performed by a laboratory that does not offer immunoblotting.

The research community is actively addressing these limitations, and a number of new testing approaches have been developed. The Public Health Service agencies have established the standard that new tests should meet or exceed the performance of two-tiered testing in order to be deemed suitable for clinical use (ASTPHLD and CDC, 1995). New approaches are either improvements in one of the steps of the two-step
testing regime or a potential alternative to two-tiered testing.

Striped blots with defined, purified antigens were FDA-approved in 2009 and are now commercially available (FDA, 2010). Viramed offer their immunoblots (Virablots) as an improvement over Western blots. Bands are striped at pre-defined positions so that calibration problems are avoided. They are read with a scanning densitometer to provide an objective measure of whether each band has sufficient colour density to be scored as a diagnostically significant reaction. Brandt et al. (2010) have devised a two-tiered procedure consisting of whole-cell ELISAs and IgG Virablots that include a new band of VlsE. Only a VlsE band would be required for a positive reaction in early Lyme disease and five or more of 11 bands in the late disease (the bands in Fig. 4.2 plus VlsE). This approach provides sensitivity comparable to or higher than standard two-tiered testing in each stage of Lyme disease, while maintaining high specificity. If adopted, it would render IgM blots obsolete. The problems of false-positive IgM blots due to over-reading of faint bands and the difficulty of knowing how long a patient has been infected would be avoided.

A second approach, developed by Zeus Scientific, seeks to avoid immunoblotting altogether by using defined peptides in a multiplex microsphere assay on the Luminex diagnostic platform. This assay, called the AtheNA Multi-Lyte test system, has been FDA-approved as a first-tier test and also evaluated with favourable results as an alternative to immunoblotting when other approved assays are used as the first-tier test (FDA, 2010; Porwancher et al., 2011).

Both the C6 peptide and whole VlsE assays have been approved as alternatives to whole-cell ELISAs as first-tier tests. In addition, the Immunetics C6 assay has recently been evaluated as an assay that could be used in place of both steps of two-tiered testing, that is, as a simple ‘stand-alone’ test. The C6 ELISA as a single step is significantly more sensitive in patients with EM than two-tiered testing (86.5 versus 35.2%, P<0.001; Wormser et al., 2011). Furthermore, the C6 assay performed comparably to two-tiered testing in sera from patients with early neuroborreliosis or Lyme arthritis. The specificity of the C6 assay was slightly less than two-tiered testing (98.9 versus 99.5%, P<0.05), however, which will be a key consideration when the assay is reviewed for approval as a stand-alone test.

Various diagnostic testing approaches will offer value to clinicians. The general practitioner may prefer a simple, objective, low-cost one-step test. The specialist may prefer the added information that immunoblots provide to diagnose atypical cases. The type and number of reactive bands offer insights about the stage of Lyme disease. Expanding profiles of reactivity with paired samples may support suspicion of ongoing infection.

4.4 Direct Assays

Two types of direct assay have been important in Lyme disease research and are useful in the laboratory diagnosis of some patients. These assays are culture of B. burgdorferi and detection of DNA by molecular methods (PCR or quantitative real-time PCR). Neither culture nor PCR are components of the routine evaluation of patients with suspected Lyme disease and no nationally standardized or FDA-approved tests are available. Both techniques have played important roles in understanding the pathogenesis of B. burgdorferi infections, however, and have assisted investigators in establishing serum banks from authenticated Lyme disease patients.

Direct detection methods have been reviewed in detail by Aguero-Rosenfeld et al. (2005) and have not changed significantly since this work was published. B. burgdorferi can be recovered from skin biopsy samples of EM patients with >95% efficiency. Efficiency of recovery is inversely correlated to the duration of EM, indicating that spirochaetes are rapidly cleared from the region of skin inoculated by tick bite. In acute EM, spirochaetes also can be grown from blood, especially high-volume plasma cultures, with recovery rates of >40%. The period of haematogenous dissemination of borreliae, however, is brief (several weeks). In later stages of the disease, blood cultures are...
Laboratory diagnostic testing for *Borrelia burgdorferi* infection is generally negative. There are only anecdotal reports of *B. burgdorferi* cultured from synovial fluid, an apparently hostile environment, and CSF. The low sensitivity of culture after the EM stage of illness (which can be treated based on the appearance of the rash) and the length of time necessary to monitor cultures (3 weeks or longer, depending on the protocol) greatly limit the clinical usefulness of bacteriological culture.

PCR is a sensitive method to detect *B. burgdorferi* DNA in skin biopsy and synovial fluid specimens (Dumler, 2001). Aguero-Rosenfeld et al. (2005) calculated median PCR sensitivities of 64% in skin biopsy samples from EM patients (four studies, range 59–87%) and 83% in synovial fluid specimens (four studies, range 76–100%). PCR has been particularly useful diagnostically in evaluating patients with treatment-resistant Lyme arthritis (Nocton et al., 1994). DNA detection methods have been less helpful in evaluating patients with neurological signs. Reported PCR sensitivities in CSF have been low and highly variable. PCR tests were positive in 38% of early and 25% of late US neuroborreliosis patients (*n* = 80; Nocton et al., 1996). Urine is not a suitable sample for PCR testing (Rauter et al., 2005).

### 4.5 Appropriate Use of Diagnostic Tests

Laboratory testing of patients without objective signs of Lyme disease or a history of potential exposure to infected vector ticks is not clinically useful. Laboratory diagnostic tests with excellent sensitivity and specificity will not have helpful predictive values if they are used inappropriately (Sackett et al., 1991). Predictive value is determined both by test characteristics (sensitivity and specificity) and, importantly, by the population in which it is used. The practice of testing patients with a low likelihood of Lyme disease can generate more false-positive results than true-positive results, resulting in mis-diagnosis and thereby harming ill people (Seltzer and Shapiro, 1996; Tugwell et al., 1997).

The positive predictive value is the probability that a patient who has a positive test result truly has Lyme borreliosis. Negative predictive value is the probability that a patient who has a negative test result does not have Lyme borreliosis. An assay with high diagnostic sensitivity improves negative predictive value, one with high diagnostic specificity improves positive predictive value.

Serological testing is recommended only for patients who have appropriate pre-test probabilities of Lyme disease in order for the results to have useful predictive values. A position paper published by the American College of Physicians (ACP) concluded that laboratory testing should be requested only for patients who have an estimated pre-test probability of Lyme disease between 0.20 and 0.80 (Tugwell et al., 1997). The ACP panel members pointed out that patients who have only non-specific signs and symptoms of illness such as headache, fatigue and muscle or joint pains, even when they reside in a geographical area endemic for Lyme disease, have a pre-test probability of Lyme disease of less than 0.20, usually much less. Patients with non-specific findings and no risk of exposure to infected ticks will have an extremely low pre-test probability.

When the pre-test probability of Lyme disease is greater than 0.80, laboratory evaluation adds little useful information (Tugwell et al., 1997). This situation only occurs in patients presenting with EM in an endemic area, as all of the other clinical manifestations of Lyme disease can be found in other conditions.

The risk of Lyme disease is geographically focal. Of more than 300,000 cases reported to the CDC over the last 15 years, most occurred in ten states of the northeast and upper midwest. Maps of reported cases of Lyme disease by county and tables of incidence by state are updated annually by the CDC and published online (CDC, 2011c). The mapped density of host-seeking *Ixodes scapularis* nymphs in the USA is consistent with the pattern of reported human cases (Diuk-Wasser et al., 2006). A ‘Lyme disease tick map’ has recently become available as an iPhone application through the Apple iTunes store (American Lyme Disease Foundation, 2010).

The concepts of positive and negative predictive value are well established and
have been described carefully elsewhere (e.g. Sackett et al., 1991; Seltzer and Shapiro, 1996; Tugwell et al., 1997). They are briefly illustrated in Table 4.1 for two different clinical situations. In both cases, diagnostic tests with good performance characteristics are assumed: 98% sensitivity and 98% specificity. In the first situation, the true frequency of disease in the population to be tested (prevalence) is only 1%. This represents the pre-test likelihood of Lyme disease in a patient with non-specific symptoms and no objective physical signs of this illness who resides in an endemic area (CDC, 2011). For patients with no history of residence in or travel to an endemic area, the prevalence of Lyme disease is much less than 1%. In the second situation, the true frequency of Lyme disease is 40%. This prevalence (or higher) is the approximate pre-test likelihood of Lyme arthritis in patients with pronounced knee swelling who reside in an endemic area (Tugwell et al., 1997).

Good tests have markedly different predictive values depending on the setting of use (Table 4.1). When the pre-test probability is 40%, the predictive values of both negative and positive results are very high (99% and 97%, respectively). However, when the pre-test probability is low, most positive test results are false positives (67%). Clinicians are currently ordering an extraordinary number of diagnostic tests for Lyme disease – more than 3.4 million tests annually, as noted above. It is critically important to the well-being of patients that tests only be used when the predictive value of a positive result is high (Fig. 4.3).

Table 4.1. Effect of disease prevalence on predictive values of diagnostic tests.

<table>
<thead>
<tr>
<th>Prevalence = 1%</th>
<th>Test positive</th>
<th>Test negative</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease</td>
<td>10</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>No disease</td>
<td>20</td>
<td>970</td>
<td>990</td>
</tr>
<tr>
<td>Total</td>
<td>30</td>
<td>970</td>
<td>1000</td>
</tr>
<tr>
<td>Predictive value of a negative result = 970/970 = 100%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Predictive value of a positive result = 10/30 = 33% (67% false positives)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prevalence = 40%</th>
<th>Test positive</th>
<th>Test negative</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease</td>
<td>392</td>
<td>8</td>
<td>400</td>
</tr>
<tr>
<td>No disease</td>
<td>12</td>
<td>588</td>
<td>600</td>
</tr>
<tr>
<td>Total</td>
<td>404</td>
<td>596</td>
<td>1000</td>
</tr>
<tr>
<td>Predictive value of a negative result = 596/596 = 99%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Predictive value of a positive result = 392/404 = 97% (3% false positives)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Illustration assumes that test sensitivity and specificity are each 98%.

Where disease is rare
Positives mostly deceive
Even with good tests

Fig. 4.3. Haiku to diagnostic testing.
References


Liang, F.T., Steere, A.C., Marques, A.R., Johnson, B.J., Miller, J.N. and Philips, M.T. (1999) Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an...


Laboratory Diagnostic Testing for Borrelia burgdorferi Infection


enzyme immunoassay and immunoblot assay are not independent tests. Clinical Infectious Diseases 30, 545–548.